Literature DB >> 8907770

Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.

G Richardson1, R W Linkins, M A Eames, D J Wood, P J Campbell, E Ankers, M Deniel, A Kabbaj, D I Magrath, P D Minor.   

Abstract

Reported are the results of a study to investigate the immunogenicity of oral poliovirus vaccine (OPV) when administered in mass campaigns compared with that following routine immunization programmes. For this purpose, paired sera were collected from a cohort of children before and after a mass vaccination with OPV in Morocco in 1987. Serum samples and information on vaccination status and other confounding factors that could influence antibody responses to OPV were collected. Neutralizing antibody titres to poliovirus types 1, 2 and 3 were determined using a standardized assay. OPV doses administered exclusively during the mass campaign were consistently associated with higher type-specific seroprevalence rates than the same number of doses administered in the routine programme. These findings could not be attributed to differences in confounding factors. Enhanced secondary spread of vaccine virus may have occurred but could not be demonstrated because of limitations in the study design. Mass campaigns appear to be highly effective in raising the dose-related poliovirus type-specific immunity of the population above that achieved by the routine immunization programme. Our findings support the continued use of mass campaigns as an adjunct to routine programmes in order to both enhance and catalyse current efforts to achieve the global eradication of poliomyelitis by the year 2000.

Entities:  

Keywords:  Africa; Age Factors; Arab Countries; Child; Delivery Of Health Care; Demographic Factors; Developing Countries; Diseases; French Speaking Africa; Health; Health Services; Immunization; Mediterranean Countries; Morocco; Northern Africa; Organization And Administration; Poliomyelitis--prevention and control; Population; Population Characteristics; Primary Health Care; Program Design; Programs; Research Methodology; Sampling Studies; Studies; Surveys; Target Population; Vaccination; Vaccines; Viral Diseases; Youth

Mesh:

Substances:

Year:  1995        PMID: 8907770      PMCID: PMC2486680     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  The Second International Standard for anti-poliovirus sera types 1, 2 and 3.

Authors:  D J Wood; A B Heath
Journal:  Biologicals       Date:  1992-09       Impact factor: 1.856

2.  Assessment and treatment by a health worker of a child who has diarrhoea.

Authors: 
Journal:  Afya       Date:  1993 Apr-Jun

Review 3.  Polio eradication from the Western Hemisphere.

Authors:  C A de Quadros; J K Andrus; J M Olive; C Guerra de Macedo; D A Henderson
Journal:  Annu Rev Public Health       Date:  1992       Impact factor: 21.981

Review 4.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.

Authors:  P A Patriarca; P F Wright; T J John
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

5.  Mass immunisation campaigns and quality of immunisation services.

Authors:  J W Bryce; F T Cutts; S Saba
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

6.  A comprehensive investigation of immunity to poliomyelitis in a developing country.

Authors:  B D Schoub; S Johnson; J M McAnerney; H G Küstner; C A van der Merwe
Journal:  Am J Epidemiol       Date:  1986-02       Impact factor: 4.897

7.  Cluster sampling to assess immunization coverage: a review of experience with a simplified sampling method.

Authors:  R H Henderson; T Sundaresan
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

  7 in total
  5 in total

Review 1.  Polio elimination in Nigeria: A review.

Authors:  Usman Nakakana Nasir; Ananda Sankar Bandyopadhyay; Francesca Montagnani; Jacqueline Elaine Akite; Etaluka Blanche Mungu; Ifeanyi Valentine Uche; Ahmed Mohammed Ismaila
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

3.  Community-acquired poliovirus infection in children with primary immunodeficiencies in Tunisia.

Authors:  Hinda Triki; Mohamed Ridha Barbouche; Olfa Bahri; Mohamed Bejaoui; Koussay Dellagi
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Assessment of immunity to polio among Rohingya children in Cox's Bazar, Bangladesh, 2018: A cross-sectional survey.

Authors:  Concepcion F Estivariz; Sarah D Bennett; Jacquelyn S Lickness; Leora R Feldstein; William C Weldon; Eva Leidman; Daniel C Ehlman; Muhammad F H Khan; Jucy M Adhikari; Mainul Hasan; Mallick M Billah; M Steven Oberste; A S M Alamgir; Meerjady D Flora
Journal:  PLoS Med       Date:  2020-03-31       Impact factor: 11.069

5.  Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?

Authors:  Sonia Resik; Alina Tejeda; Ondrej Mach; Magile Fonseca; Manuel Diaz; Nilda Alemany; Lai Heng Hung; Yoan Aleman; Ileana Mesa; Gloria Garcia; Roland W Sutter
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.